The research compound in Egrifta®
Egrifta® is a HIV-associated lipodystrophy medicine from Theratechnologies. Its active compound is Tesamorelin — which is what this catalogue supplies, as a research material.
This is not Egrifta®, and NOVALYTE LABS has no affiliation with Theratechnologies. We supply the compound Tesamorelin for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Egrifta® is a trademark of Theratechnologies, referenced here only to identify the compound.
Egrifta is the brand under which tesamorelin is marketed, for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, stabilised against enzymatic degradation, and acts on the pituitary rather than supplying growth hormone directly.
Tesamorelin is supplied here as a research material, not as the branded medicine.
Tesamorelin in this catalogue
10mg vial
How Tesamorelin is supplied here
Everything below describes the research material in this catalogue, not the medicine.
| Compound | Tesamorelin |
|---|---|
| Presentation | 10mg vial |
| Dosage options | 10mg |
| Research category | Growth Research |
| Batch COA | Certificate supplied with order |
| Availability | In stock |
| Intended use | Laboratory research only — not for human or veterinary use |
Common questions
What is the active compound in Egrifta?
Tesamorelin. Egrifta is a registered trademark of Theratechnologies, approved for HIV-associated lipodystrophy.
Is this Egrifta?
No. NOVALYTE LABS supplies Tesamorelin as a research material with batch documentation. It is not Egrifta, it is not a medicine, it is not supplied for human use, and there is no affiliation with Theratechnologies.
Can I buy Egrifta here?
No. Egrifta is a prescription medicine sold by Theratechnologies. This catalogue supplies Tesamorelin, the compound it is built on, as a laboratory research material only.